UNASSIGNED: Asthma is a common, chronic and heterogeneous syndrome, affecting @entity1 of all ages, all races and both sexes. It may range from mild disease with barely noticeable symptoms, to very severe disease with constant symptoms that greatly hinder the life of the @entity1 . Guidelines issued by various medical societies provide guidance on how to diagnose and manage @entity748 @entity1 . It is now increasingly recognised that @entity565 management must be individualised, tailored not only to the severity of the disease but to the phenotypic characteristics of each @entity1 . The aim of @entity565 treatment is control of @entity565 and the prevention of risk of exacerbations and fixed airflow limitation. Asthma control can be easily assessed clinically through simple screening tools such as the use of validated questionnaires and spirometry. The use of inflammatory biomarkers can be an alternative approach that, however, requires more time and resources. Asthma treatment involves the use of controllers, mainly inhaled @entity288 and long-acting b2-agonists, and relievers, mainly rapid-acting b2-agonists. Controller medications reduce airway inflammation, lead to better symptom control and reduce the risk of future exacerbations. Reliever (rescue) medications alleviate symptoms and prevent exercise-induced bronchoconstriction. Treatment must be based on a "stepwise approach" in order to achieve good control of symptoms and to minimise future risks of exacerbations. That is, less treatment for mild disease, more treatment for severe, uncontrolled disease. Once good @entity565 control has been achieved and maintained, treatment should be stepped down. In severe @entity748 , phenotypic characterisation becomes more clinically useful and add-on treatment such as anti-immunoglobulin E monoclonal antibodies may be required. Despite our better understanding of @entity565 , there are still @entity1 who will not respond to treatment and remain symptomatic. Dissemination of guidelines and national plans allowing early diagnosis of @entity565 as well as access to specialised primary and secondary care for @entity748 @entity1 , personalised treatment and continuity of care may lead to excellence in care and controlled @entity565 for the majority of @entity1 . Education of the @entity1 in @entity565 is also very important, as in every chronic disease, as the @entity1 live with the disease every day while they visit a healthcare professional a few times a year. Future planning for new treatments should focus on the needs of such severe @entity565 @entity1 .

Clinical XXXX phenotypes in the real world: opportunities and challenges.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'people'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic', 'asthmatics'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity565 :: (MESH:D001249,Disease) :: ['asthma']
